Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO

Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker
                             as President and CEO

Wholly Owned Subsidiary of medac GmbH to Launch Company's U.S. Presence

PR Newswire

CHICAGO, Oct. 16, 2013

CHICAGO, Oct. 16, 2013 /PRNewswire/ --Medac Pharma, Inc., a privately held
pharmaceutical company focused on the development of new molecules and
improving the effectiveness of existing medicines, has announced the
appointment of Terri Shoemaker as President and CEO.

Located in Chicago, IL, Medac Pharma, Inc. is the wholly owned subsidiary of
medac GmbH, a global pharmaceutical company that has been developing,
manufacturing and marketing pharmaceuticals for more than 40 years in 70
countries.

"With the experience and resources of our parent company, we're
well-positioned to bring clinically tested products to the U.S. that have the
potential to improve quality of life for patients across multiple diseases,"
said Ms. Shoemaker. 

Prior to joining Medac Pharma, Inc., Ms. Shoemaker served as Vice President of
Sales at InterMune, Inc. where she developed a large-scale commercial sales
infrastructure in preparation for the launch of a treatment for idiopathic
pulmonary fibrosis. Before joining InterMune, Inc. in 2009, Ms. Shoemaker
co-founded BioPharm Strategic Solutions, providing pre-commercial, commercial,
operational and strategic guidance for start-up pharmaceutical and
biotechnology organizations. In 2002, Ms. Shoemaker joined Pharmion
Corporation, serving as National Sales Director and then Sr. Director U.S.
Commercial Operations, building and leading its specialty oncology
organization. In 2008, when Celgene Corporation acquired Pharmion
Corporation, Ms. Shoemaker remained as Executive Director of Strategic
Commercial Operations, working as part of the executive transition team
charged with building the new and fully aligned commercial organization.

For 15 years prior to Pharmion Corporation, Ms. Shoemaker held multiple
leadership positions at DuPont Pharmaceuticals, which was acquired by Bristol
Myers Squibb in 2000, including Senior Director of Sales, Director of Clinical
Development & Education and Director Marketing and Health Management.

Under the leadership of Ms. Shoemaker, Medac Pharma Inc.'s initial focus will
be on autoimmune diseases and oncology. The company's lead product candidate
is being developed to optimize methotrexate, a foundational drug critical to
many therapeutic regimens.

Ulrich Kosciessa, Managing Director for medac GmbH and Chairman of Medac
Pharma Inc.'s Board of Directors, stated, "We're delighted to have elected Ms.
Shoemaker as President and CEO of Medac Pharma, Inc. With more than 25 years
experience in the biotech and pharmaceutical industry, her expertise will be
an invaluable resource as we advance our business efforts in the U.S."

In addition to her appointment as President and CEO, Ms. Shoemaker has been a
board member of Medac Pharma, Inc. since June 2012. Supporting Ms. Shoemaker,
Medac Pharma, Inc.'s management team previously worked together and brings a
successful performance history to the company. 

Medac Pharma, Inc. will continue expanding its Chicago-based team in the
coming months as it approaches the launch of its first product and the
in-licensing of additional products from medac GmbH. In oncology alone, medac
GmbH markets nearly 40 products outside the U.S., establishing an opportunity
for Medac Pharma, Inc. to in-license and sell multiple products from its
parent company. Concurrently, given Medac Pharma, Inc.'s development and
commercialization capabilities, it is well positioned to partner with other
companies seeking ways to penetrate the U.S. market.

About Medac Pharma, Inc.

Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known
and respected global pharmaceutical company that has been making scientific
and therapeutic discoveries for more than 40 years.

Medac Pharma, Inc. is focused on developing therapies with the potential to
make meaningful differences in patients' lives. The company's approach is to
improve existing agents by enhancing the mode of delivery, addressing safety
profiles and inventing ways to maximize efficacy.

For more information, please visit www.medacpharma.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Medac Pharma, Inc.

Website: www.medacpharma.com
 
Press spacebar to pause and continue. Press esc to stop.